Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa

NCT06716814 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT06716814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 3
Overall status
Recruiting
Start date
March 6, 2025
Completion date
March 31, 2027
Enrollment
104 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a (moderate or severe)